Table 6. Pooled incremental net monetary benefit (2020 USD) and percent reduction in active TB incidence comparing TPT to no TPT.
| Value | τ | I 2 | |||||
|---|---|---|---|---|---|---|---|
| Estimate | 95% CI | p-value | Estimate | 95% CI | Estimate | 95% CI | |
| LMICs | |||||||
| Pooled incremental net monetary benefit (n = 10) | $271 | −$81 to $622 | 0.12 | $441 | $164 to $909 | 67% | 35% to 83% |
| Pooled percent reduction in active TB Incidence (n = 23) | 20% | 13% to 27% | <0.001 | 15% | 11% to 21% | 96% | 95% to 97% |
| Among strategies that have a time horizon <5 years (n = 3) | 10% | −22% to 43% | 0.42 | 11% | 5% to 34% | 96% | 91% to 98% |
| Among strategies that have a time horizon ≥5 years (n = 20) | 21% | 13% to 28% | <0.001 | 15% | 11% to 24% | 96% | 95% to 97% |
| Among strategies that include an INH regimen 6 to 12 months long (n = 13)* | 17% | 8% to 26% | 0.001 | 14% | 9% to 23% | 95% | 93% to 97% |
| Among strategies that include an INH regimen longer than 12 months (n = 6)* | 24% | 3% to 45% | 0.04 | 20% | 8% to 55% | 86% | 73% to 93% |
| HICs | |||||||
| Pooled incremental net monetary benefit (n = 2) | $2,568 | −$32,115 to $37,251 | 0.52 | $2,122 | NA | 0% | NA |
| Pooled percent reduction in active TB incidence (n = 3) | 37% | −34% to 100% | 0.13 | 25% | 12% to 82% | 95% | 88% to 98% |
τ = square root of between study variance; I2 = measure of heterogeneity.
* There are only 19 strategies that were eligible for stratification by TPT regimen category. The other 4 strategies did not report duration of INH.
CI, confidence interval; HIC, high-income country; INH, isoniazid; LMIC, low- and middle-income country; TB, tuberculosis; TPT, tuberculosis preventive treatment; USD, United States dollar.